Header menu link for other important links
X
p-Benzoquinone-induced aggregation and perturbation of structure and chaperone function of alpha-crystallin is a causative factor of cigarette smoke-related cataractogenesis
ARITRA CHOWDHURY, APARAJITA CHOUDHURY, SHRUTI CHAKRABORTY, ARUNAVA GHOSH, VICTOR BANERJEE, SHINJINI GANGULY, GAUTAM BHADURI, RAJAT BANERJEE, KALIPADA DAS, INDU B CHATTERJEE
Published in ELSEVIER IRELAND LTD
2018
Volume: 394
   
Pages: 11 - 18
Abstract
Cigarette smoking is a significant risk factor for cataract. However, the mechanism by which cigarette smoke (CS) causes cataract remains poorly understood. We had earlier shown that in CS-exposed guinea pig, p-benzoquinone (p-BQ) derived from CS in the lungs is carried by the circulatory system to distant organs and induces various smoke-related pathogeneses. Here, we observed that CS exposure caused accumulation of the p-BQ-protein adduct in the eye lens of guinea pigs. We also observed accumulation of the p-BQ-protein adduct in resected lens from human smokers with cataract. No such accumulation was observed in the lens of never smokers. p-BQ is a strong arylating agent that forms Michael adducts with serum albumin and haemoglobin resulting in alterations of structure and function. A major protein in the mammalian eye lens is alpha A-crystallin, which is a potent molecular chaperone. alpha A-crystallin plays a key role in maintaining the integrity and transparency of the lens. SDS-PAGE indicated that p-BQ induced aggregation of alpha A-crystallin. Various biophysical techniques including UV-vis spectroscopy, fluorescence spectroscopy, FT-IR, bis-ANS titration suggested a perturbation of structure and chaperone function of alpha A-crystallin upon p-BQ modification. Our results indicate that p-BQ is a causative agent involved in the modification of alpha A-crystallin and pathogenesis of CS-induced cataract. Our findings would educate public about the impacts of smoking on eye health and help to discourage them from smoking. The study might also help scientists to develop new drugs for the intervention of CS-induced cataract at an early stage.
About the journal
JournalData powered by TypesetToxicology
PublisherData powered by TypesetELSEVIER IRELAND LTD
ISSN0300-483X